JP2017514911A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017514911A5 JP2017514911A5 JP2017510458A JP2017510458A JP2017514911A5 JP 2017514911 A5 JP2017514911 A5 JP 2017514911A5 JP 2017510458 A JP2017510458 A JP 2017510458A JP 2017510458 A JP2017510458 A JP 2017510458A JP 2017514911 A5 JP2017514911 A5 JP 2017514911A5
- Authority
- JP
- Japan
- Prior art keywords
- administered
- ritonavir
- lonafamib
- dose
- interferon
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- NCDNCNXCDXHOMX-UHFFFAOYSA-N Ritonavir Natural products C=1C=CC=CC=1CC(NC(=O)OCC=1SC=NC=1)C(O)CC(CC=1C=CC=CC=1)NC(=O)C(C(C)C)NC(=O)N(C)CC1=CSC(C(C)C)=N1 NCDNCNXCDXHOMX-UHFFFAOYSA-N 0.000 claims description 20
- NCDNCNXCDXHOMX-XGKFQTDJSA-N ritonavir Chemical compound N([C@@H](C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1SC=NC=1)CC=1C=CC=CC=1)C(=O)N(C)CC1=CSC(C(C)C)=N1 NCDNCNXCDXHOMX-XGKFQTDJSA-N 0.000 claims description 20
- 229960000311 ritonavir Drugs 0.000 claims description 20
- 241000724709 Hepatitis delta virus Species 0.000 claims description 8
- 208000037262 Hepatitis delta Diseases 0.000 claims description 7
- 208000029570 hepatitis D virus infection Diseases 0.000 claims description 7
- 208000015181 infectious disease Diseases 0.000 claims description 4
- 239000003795 chemical substances by application Substances 0.000 claims description 3
- 239000003814 drug Substances 0.000 claims 16
- 102000014150 Interferons Human genes 0.000 claims 10
- 108010050904 Interferons Proteins 0.000 claims 10
- 229940079322 interferon Drugs 0.000 claims 10
- 239000002552 dosage form Substances 0.000 claims 6
- DHMTURDWPRKSOA-RUZDIDTESA-N lonafarnib Chemical compound C1CN(C(=O)N)CCC1CC(=O)N1CCC([C@@H]2C3=C(Br)C=C(Cl)C=C3CCC3=CC(Br)=CN=C32)CC1 DHMTURDWPRKSOA-RUZDIDTESA-N 0.000 claims 6
- 229950001750 lonafarnib Drugs 0.000 claims 6
- 102000006992 Interferon-alpha Human genes 0.000 claims 4
- 108010047761 Interferon-alpha Proteins 0.000 claims 4
- 238000011278 co-treatment Methods 0.000 claims 3
- 229940000425 combination drug Drugs 0.000 claims 1
- 238000011262 co‐therapy Methods 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 238000000034 method Methods 0.000 description 10
- FELGMEQIXOGIFQ-CYBMUJFWSA-N (3r)-9-methyl-3-[(2-methylimidazol-1-yl)methyl]-2,3-dihydro-1h-carbazol-4-one Chemical compound CC1=NC=CN1C[C@@H]1C(=O)C(C=2C(=CC=CC=2)N2C)=C2CC1 FELGMEQIXOGIFQ-CYBMUJFWSA-N 0.000 description 2
- 208000009011 Cytochrome P-450 CYP3A Inhibitors Diseases 0.000 description 2
- HYPPXZBJBPSRLK-UHFFFAOYSA-N diphenoxylate Chemical compound C1CC(C(=O)OCC)(C=2C=CC=CC=2)CCN1CCC(C#N)(C=1C=CC=CC=1)C1=CC=CC=C1 HYPPXZBJBPSRLK-UHFFFAOYSA-N 0.000 description 2
- XUFQPHANEAPEMJ-UHFFFAOYSA-N famotidine Chemical compound NC(N)=NC1=NC(CSCCC(N)=NS(N)(=O)=O)=CS1 XUFQPHANEAPEMJ-UHFFFAOYSA-N 0.000 description 2
- 229960001596 famotidine Drugs 0.000 description 2
- 229940087973 lomotil Drugs 0.000 description 2
- 239000003607 modifier Substances 0.000 description 2
- 229960005343 ondansetron Drugs 0.000 description 2
- 229940069428 antacid Drugs 0.000 description 1
- 239000003159 antacid agent Substances 0.000 description 1
- 230000003474 anti-emetic effect Effects 0.000 description 1
- 229940125714 antidiarrheal agent Drugs 0.000 description 1
- 239000003793 antidiarrheal agent Substances 0.000 description 1
- 229940125683 antiemetic agent Drugs 0.000 description 1
- 239000002111 antiemetic agent Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461987315P | 2014-05-01 | 2014-05-01 | |
| US61/987,315 | 2014-05-01 | ||
| US201462044766P | 2014-09-02 | 2014-09-02 | |
| US62/044,766 | 2014-09-02 | ||
| US201462073413P | 2014-10-31 | 2014-10-31 | |
| US62/073,413 | 2014-10-31 | ||
| US201562151349P | 2015-04-22 | 2015-04-22 | |
| US62/151,349 | 2015-04-22 | ||
| PCT/US2015/028933 WO2015168648A1 (en) | 2014-05-01 | 2015-05-01 | Treatment of hepatitis delta virus infection |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017514911A JP2017514911A (ja) | 2017-06-08 |
| JP2017514911A5 true JP2017514911A5 (enExample) | 2018-11-01 |
| JP6490800B2 JP6490800B2 (ja) | 2019-03-27 |
Family
ID=54359409
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017510458A Active JP6490800B2 (ja) | 2014-05-01 | 2015-05-01 | デルタ型肝炎ウイルス感染の処置 |
Country Status (13)
| Country | Link |
|---|---|
| EP (2) | EP3620163A1 (enExample) |
| JP (1) | JP6490800B2 (enExample) |
| KR (3) | KR102686313B1 (enExample) |
| CN (2) | CN106535895B (enExample) |
| CY (1) | CY1121924T1 (enExample) |
| DK (1) | DK3137078T3 (enExample) |
| ES (1) | ES2728405T3 (enExample) |
| HU (1) | HUE044606T2 (enExample) |
| LT (1) | LT3137078T (enExample) |
| PL (1) | PL3137078T3 (enExample) |
| PT (1) | PT3137078T (enExample) |
| SI (1) | SI3137078T1 (enExample) |
| WO (1) | WO2015168648A1 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11311519B2 (en) | 2014-05-01 | 2022-04-26 | Eiger Biopharmaceuticals, Inc. | Treatment of hepatitis delta virus infection |
| US10076512B2 (en) | 2014-05-01 | 2018-09-18 | Eiger Biopharmaceuticals, Inc. | Treatment of hepatitis delta virus infection |
| US10835496B2 (en) | 2015-04-21 | 2020-11-17 | Eiger Biopharmaceuticals, Inc. | Pharmaceutical compositions comprising lonafarnib and ritonavir |
| EP3370723B1 (en) * | 2015-11-04 | 2020-12-16 | Eiger Biopharmaceuticals, Inc. | Treatment of hepatitis delta virus infection |
| LT3416675T (lt) | 2016-02-19 | 2021-06-25 | Eiger Biopharmaceuticals, Inc. | Hepatito delta viruso infekcijos gydymas interferonu lambda |
| US11801371B2 (en) | 2017-03-01 | 2023-10-31 | National University Of Singapore | Microneedle device |
| WO2024223797A1 (en) * | 2023-04-28 | 2024-10-31 | Institut National de la Santé et de la Recherche Médicale | Use of cyp3a4 inhibitors for the treatment of hepatitis d virus (hdv) infections |
| WO2025240246A1 (en) * | 2024-05-13 | 2025-11-20 | Gilead Sciences, Inc. | Combination therapies with ribavirin |
| WO2025240244A1 (en) | 2024-05-13 | 2025-11-20 | Gilead Sciences, Inc. | Combination therapies comprising bulevirtide and lonafarnib for use in the treatment of hepatitis d virus infection |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6936694B1 (en) | 1982-05-06 | 2005-08-30 | Intermune, Inc. | Manufacture and expression of large structural genes |
| US5382657A (en) | 1992-08-26 | 1995-01-17 | Hoffmann-La Roche Inc. | Peg-interferon conjugates |
| US5951974A (en) | 1993-11-10 | 1999-09-14 | Enzon, Inc. | Interferon polymer conjugates |
| US5981709A (en) | 1997-12-19 | 1999-11-09 | Enzon, Inc. | α-interferon-polymer-conjugates having enhanced biological activity and methods of preparing the same |
| US6627223B2 (en) | 2000-02-11 | 2003-09-30 | Eurand Pharmaceuticals Ltd. | Timed pulsatile drug delivery systems |
| CA2424222A1 (en) * | 2000-10-02 | 2002-04-11 | Merck & Co., Inc. | Inhibitors of prenyl-protein transferase |
| ES2318000T3 (es) * | 2001-02-15 | 2009-05-01 | Janssen Pharmaceutica Nv | Combinaciones de inhibidores de la farnesil-protein-transferasa con agentes antiestrogenos. |
| WO2005117864A1 (en) * | 2004-05-28 | 2005-12-15 | Astrazeneca Ab | Combination product comprising anastrozole and a dual prenyl transferase inhibitor |
| US20080021078A1 (en) | 2006-07-18 | 2008-01-24 | Horizon Therapeutics, Inc. | Methods and medicaments for administration of ibuprofen |
| JP2009530382A (ja) * | 2006-03-23 | 2009-08-27 | シェーリング コーポレイション | Ｈｃｖプロテアーゼインヒビターとｃｙｐ３ａ４インヒビターとの組み合わせ、および関連する処置方法 |
| US8067033B2 (en) | 2007-11-30 | 2011-11-29 | Horizon Pharma Usa, Inc. | Stable compositions of famotidine and ibuprofen |
| WO2008137692A1 (en) * | 2007-05-03 | 2008-11-13 | Link Medicine Corporation | Treatment of synucleinopathies |
| US20090087483A1 (en) | 2007-09-27 | 2009-04-02 | Sison Raymundo A | Oral dosage combination pharmaceutical packaging |
| WO2010009432A1 (en) | 2008-07-17 | 2010-01-21 | Horizon Therapeutics, Inc. | Nsaid dose unit formulations with h2-receptor antagonists and methods of use |
| MY169734A (en) * | 2009-04-25 | 2019-05-14 | Hoffmann La Roche | Methods for improving pharmacokinetics |
| WO2011088126A2 (en) * | 2010-01-13 | 2011-07-21 | Eiger Biopharmaceuticals, Inc. | Treatment of viral infection with prenyltransferase inhibitors |
-
2015
- 2015-05-01 KR KR1020167033817A patent/KR102686313B1/ko active Active
- 2015-05-01 JP JP2017510458A patent/JP6490800B2/ja active Active
- 2015-05-01 EP EP19162000.4A patent/EP3620163A1/en active Pending
- 2015-05-01 LT LTEP15785846.5T patent/LT3137078T/lt unknown
- 2015-05-01 EP EP15785846.5A patent/EP3137078B1/en active Active
- 2015-05-01 ES ES15785846T patent/ES2728405T3/es active Active
- 2015-05-01 PT PT15785846T patent/PT3137078T/pt unknown
- 2015-05-01 HU HUE15785846 patent/HUE044606T2/hu unknown
- 2015-05-01 CN CN201580023585.1A patent/CN106535895B/zh active Active
- 2015-05-01 DK DK15785846.5T patent/DK3137078T3/da active
- 2015-05-01 SI SI201530762T patent/SI3137078T1/sl unknown
- 2015-05-01 PL PL15785846T patent/PL3137078T3/pl unknown
- 2015-05-01 CN CN202010069655.XA patent/CN111265525A/zh active Pending
- 2015-05-01 KR KR1020237014993A patent/KR20230062688A/ko not_active Ceased
- 2015-05-01 KR KR1020247023478A patent/KR20240112990A/ko active Pending
- 2015-05-01 WO PCT/US2015/028933 patent/WO2015168648A1/en not_active Ceased
-
2019
- 2019-05-29 CY CY20191100571T patent/CY1121924T1/el unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5869469B2 (ja) | 鉄が病因に関与する肝臓疾患の処置 | |
| RU2329050C2 (ru) | Комбинация ингибиторов цитохром-р450-зависимых протеаз | |
| JP2022527359A5 (enExample) | ||
| JP2015505565A5 (enExample) | ||
| Zhang et al. | Current targeted therapeutics against COVID-19: based on first-line experience in China | |
| CN109952101A (zh) | 治疗高细胞因子血症和病毒感染的肥大细胞稳定剂 | |
| JP2013518124A5 (enExample) | ||
| JP2002528502A5 (enExample) | ||
| JP2018532797A5 (enExample) | ||
| Khatri et al. | Nitazoxanide/Camostat combination for COVID-19: an unexplored potential therapy | |
| CN106535895A (zh) | 丁型肝炎病毒感染的治疗 | |
| CA2525202A1 (en) | Use of alpha interferon, ribavirin, dsrna and neuraminidase inhibitors to treat avian influenza | |
| JP2016505050A5 (enExample) | ||
| Winkler et al. | Correspondence on ‘Interleukin-6 receptor blockade with subcutaneous tocilizumab in severe COVID-19 pneumonia and hyperinflammation: case–control study’ | |
| JP2007501806A5 (enExample) | ||
| JP2023531930A5 (enExample) | ||
| DE69328667D1 (de) | Flavopereirine enthaltende zusammensetzung und ihre anwendung in der behandlung gegen hiv-viren | |
| JP2021523129A5 (enExample) | ||
| RU2013129824A (ru) | Новое лечение инфекции вируса гепатита с | |
| WO2022123323A1 (en) | A pharmaceutical composition of artesunate and mefloquine and method thereof | |
| RU2014116988A (ru) | Алиспоривир для лечения инфекции, вызванной вирусом гепатита с | |
| RU2013148539A (ru) | Алиспоривир для лечения инфекции вируса гепатита с | |
| JP2021521227A5 (enExample) | ||
| CN117243946A (zh) | 瑞香素及包含其的组合物在制备治疗心肌炎药物中的应用 | |
| EA049592B1 (ru) | СПОСОБ ЛЕЧЕНИЯ РНК ВИРУСНЫХ ИНФЕКЦИЙ, В ТОМ ЧИСЛЕ COVID-19 (SARS-CoV-2) |